All News
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Still's disease is an autoinflammatory disease characterized by spiking fever, rash, polyarthralgia, sore throat and even life-threatening complications, such as macrophage activation syndrome. It was first described by George Still in the late 1800s.
Read Article
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
Opening Day Report
The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
Read Article
#ACR21 #pedsrheum
I say it counts!
I mean, at the end of the day, these are all just pictures of food on the internet, right?
#ACRBakeAnythingChallenge https://t.co/bVQuealWWX
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
New dimensions in cellular immunology. Great session, some which I understood. Kids with #JIA have more cytolytic pathway missense - some leads to macrophage activation syndrome #MAS Low NK cells in Juvenile Dermatomyositis. 9T112 #ACR21 @RheumNow https://t.co/5lUkqr65UM
Janet Pope Janetbirdope ( View Tweet)
Can you stop monitoring eyes in + ANA and/or pauciarticular pt who becomes an adult if no uveitis ever, in last 5 yrs, etc. When can we stop looking? #AVR21 @RheumNow https://t.co/1Ml1BuJD7Y
Janet Pope Janetbirdope ( View Tweet)
#ACR21
#pedsrheum
Risk factors for poor outcomes: delay to diagnosis, poor access to therapy, poor access to care https://t.co/SlFyav5KV6
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Please don’t miss MISC (pronounced Miss C)=multisystem inflammatory syndrome. Pediatric syndrome post #SARSCoV2 infection. May go w macrophage activation syndrome (MAS) w distinct proteomics signature. Potentially v poor outcomes. Need to dx and treat #ACR21 abst0961 @RheumNow https://t.co/uaBbUdg3lt
Janet Pope Janetbirdope ( View Tweet)
#ACR21 #pedsrheum
juvenile localized scleroderma
Polypositive profile
3 or more autos correlated with more severe skin score, more activity https://t.co/vVXV4jjLvG
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans :
-Step up
-Early combination
-Biologic first
Which one do you think works best?
I'd say none: overall 40-60% not achieving CDI off steroids at 24 months.
Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
✨Great Pearls when screening patients for clinically suspect #Scleroderma or #Juvenile #Dermatomyositis
📌 Don’t Stop Work Up at Negative ANA if strongly suspect SSc
📌 #Myositis Specific Antibodies have different phenotypes in kids than adults (MDA-5, TIF-1g, NXP-2)
#ACR21 https://t.co/KrkkzA5bkV
Ashima Makol MD AshimaMakol ( View Tweet)
Nationwide study - low income - greater length of stay than highest income. Lowest income many be supported but those who do not have those resources may have an increased length of stay in children hospitalized with pediatric #lupus @dsoulsMD @rheumnow #ACR21 abst#0768 https://t.co/j7VDpVW7ND
Bella Mehta bella_mehta ( View Tweet)
Plenary at #ACR21 Renal outcome Risk of minority patients with pediatric #lupus @rheumnow abst#0956
inpatient hospitalizations. https://t.co/HK8w246Dsn
Bella Mehta bella_mehta ( View Tweet)
"We need to do more than improving quality of care to close the gap in racial disparities." - Dr. J Chang
Trends of adverse renal outcomes⬇️w/time in children hosp w/SLE. Improvements seen across racial/ethnic group, but black-white disparity persists abst#0956 #ACR21 @rheumnow https://t.co/HcOwQiKCb2
TheDaoIndex KDAO2011 ( View Tweet)
TNFi + JIA = watch the skin! A nearly 3fold increase of paradoxal psoriasis in JIA patients exposed to TNFi reported in the CARRA registry w/ incidence rate the highest on children receiving adalimumab.
#Abst0241 @RheumNow #ACR2021 https://t.co/uXOwV2RlGu https://t.co/8f8mvVUkV2
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation
Regional Winner of Europe & Central Asia
Image Competition: Rheum Dz in Patients of Color
#ACR21 @rheumnow https://t.co/vxayxgINa8
TheDaoIndex KDAO2011 ( View Tweet)
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Emilio Martin Mola emartinmola ( View Tweet)
Retrospective study hospitalized new-onset systemic JIA (2008-19):52 children’s hospitals & 534 sJiAshows 29% rx w/ biologics & 58% steroids. Over time Biologic use increased & MTX decreased. Biologic correlated w/ Hi hospital volume, ICU stay, later years https://t.co/blbOps9zVQ
Links:
Dr. John Cush RheumNow ( View Tweet)
